FINWIRES · TerminalLIVE
FINWIRES

調査速報:AOS第1四半期:中国経済の軟化により業績見通しを下方修正

By

-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。A.O. Smithは、2026年第1四半期の業績が期待外れだったと発表しました。売上高は2%減の9億4,560万ドル、1株当たり利益(EPS)は11%減の0.85ドルとなり、市場予想の0.94ドルを下回りました。この四半期は、中国市場の低迷(現地通貨ベースで17%減)と北米の住宅需要の軟調が継続したことを反映しており、売上高は1%増加したものの、北米セグメントの利益率は140ベーシスポイント低下し、23.3%となりました。操業上の課題としては、テネシー州の工場における天候による操業停止や、中国における消費者需要の低迷が挙げられます。中国以外の地域における売上高は11%減少しました。経営陣は2026年通期の業績見通しを引き下げ、EPSを3.85~4.15ドルから3.70~4.00ドルに、売上高成長率を2~5%から2~4%にそれぞれ下方修正しました。収益面で逆風が吹く中、同社は力強いキャッシュ創出能力を示し、営業キャッシュフローは234%増の1億2940万ドル、フリーキャッシュフローは583%増の1億1890万ドルとなり、5130万ドルの自社株買いが可能となった。また、第2四半期の税引前費用2000万ドルで、北米水処理事業の計画的な再編も支援した。

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Firstenergy Corp.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target by $1 to $55, 20.0x our next-12-month EPS view of $2.75, a premium to its five-year average of 15.6x. We reduce our 2026 EPS view by $0.02 to $2.72 and 2027 EPS by $0.01 to $2.93. The Q1 core EPS increase (+7.5% Y/Y) breaks a three-quarter streak of declines, and we see continued momentum throughout our forecast horizon. We see positive data center demand trends, with long-term contracted demand (4.3 GW) up 4% since February 2026 (4.1 GW) and up 47% since February 2025 (2.9 GW), while pipeline demand (14.9 GW) is up 15% since February 2026 (12.9 GW) and has more than doubled since February 2025 (6.1 GW). FE has reduced base O&M by over $200M (15%) since 2022, with Q1 2026 showing an additional ~5% YoY decline, while simultaneously improving reliability metrics. We think FE's cost discipline, service quality improvement, and competitive rate positioning should translate into more favorable rate case outcomes, reduced disallowance risk, and potentially higher allowed ROEs.

$FE
Sectors

Sector Update: Consumer

Consumer stocks were higher Thursday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) rising 1.4% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increasing 0.4%.In corporate news, Lamb Weston (LW) shares rose 1.6% after shareholder Starboard Value said in a letter to the board Thursday that the company should hold an investor day and reset earnings to a normalized level.

$LW
Australia

Market Chatter: FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug

The US Food and Drug Administration's Oncology Drugs Advisory Committee rejected the benefits AstraZeneca's (AZN) Camizestrant drug candidate to treat breast cancer, Bloomberg reported Thursday.Six committee members voted against the drug due to disagreement over the trial design and the potential implications in the clinical setting, according to Bloomberg.The drug trial met is primary endpoint of progression-free survival as well as the progression-free survival 2 endpoint, however, FDA does not consider PFS2 a suitable endpoint for regulatory decision making, according to a briefing document.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $189.60, Change: $+4.40, Percent Change: +2.37%

$AZN